Bladder cancer (BC) is the fifth most frequent cancer found in the United States (US). Tobacco smoke (TS) is the major cause of BC in US, and tobacco smokers have a 5-fold higher BC incidence than nonsmokers. TS contains more than 60 carcinogens;however, which carcinogens are responsible for BC is not well established. Arylamines, 4-hydroxy-aminoblphenyl (ABP) in particular, are the major cause of occupation-related BC, but the amount of arylamines in TS is minute. In fact, TS contains 100,000 fold more acrolein (Acr) than ABP, and Acr is a potent and organ-specific carcinogen capable of Inducing BC in rat models. Our laboratory has a longstanding interest in studying the role of chemical carcinogen induced DNA damage and repair in tumorigenesis. We recently made three important findings regarding Acr: (1) Acr damages DNA by forming Acr-DNA adducts that are mutagenic;(ii) Acr inhibits DNA repair by modifying and accelerating autophagy-mediated degradation of the modified DNA repair proteins;and (iii) Acr-DNA adducts are poorly repaired in human cells. We propose that Acr Is a major bladder carcinogen and its carcinogenicity Is via these three detrimental effects (Hypothesis 1). Most BC can be classified as either noninvasive (N-lnv) or invasive (Inv);while N-lnv-BC often bear mutations in codon 12 ofthe H-RAS (<20%) and codons 248, 249, 372 and 652 ofthe FGFRS gene (80%), Inv-BC mainly carry mutations in the p53 (30-60%) and RB genes. We hypothesize that these mutation hotspots in BC are Acr preferential binding sites in bladder urothelial cells (Hypothesis 2). We found that DNA damage induces much higher mutations in Inv-BC cells than in N-lnv-BC cells and that N-lnv-BC cells have a much higher DNA damage repair capacity than Inv-BC cells. We also recently found that p63 gene is highly expressed in N-lnv-BC but not in Inv-BC cells, and that introduction of p63 gene elevates DNA repair capacity in Inv-BC cells. These results lead us to hypothesize that H- RAS/FGFR3 mutation-activation enhances DNA repair capacity via activation of p63 and that p53 mutations reduce DNA repair capacity via down regulation of p63 (Hypothesis 3). We will test these hypotheses in cultured human urothelial cells, human bladder tumor tissue samples and transgenic mouse models to understand the relationship between DNA repair capacity and divergent pathways of bladder cancer.

Public Health Relevance

Tobacco smoke (TS) is believed to be the cause of half of all bladder cancer, but the exact cancer-causing carcinogen in TS remains elusive. Our studies will help define the type of carcinogen and how it causes different levels of DNA damage in different types of bladder cancer. Our results should provide novel insights into the pathogenesis of bladder cancer and how this prevalent disease can be better prevented.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
1P01CA165980-01A1
Application #
8596898
Study Section
Special Emphasis Panel (ZCA1-RPRB-B (M2))
Project Start
2013-09-12
Project End
2018-08-31
Budget Start
2013-09-12
Budget End
2014-08-31
Support Year
1
Fiscal Year
2013
Total Cost
$218,176
Indirect Cost
$88,713
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Zeng, Xingruo; Xu, Zhou; Gu, Jiayan et al. (2016) Induction of miR-137 by Isorhapontigenin (ISO) Directly Targets Sp1 Protein Translation and Mediates Its Anticancer Activity Both In Vitro and In Vivo. Mol Cancer Ther 15:512-22
Xu, Zhou; Zeng, Xingruo; Xu, Jiawei et al. (2016) Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis. Neuro Oncol 18:830-9
Zhou, Haiping; He, Feng; Mendelsohn, Cathy L et al. (2016) FGFR3b Extracellular Loop Mutation Lacks Tumorigenicity In Vivo but Collaborates with p53/pRB Deficiency to Induce High-grade Papillary Urothelial Carcinoma. Sci Rep 6:25596
Wang, Y; Xu, J; Gao, G et al. (2016) Tumor-suppressor NFκB2 p100 interacts with ERK2 and stabilizes PTEN mRNA via inhibition of miR-494. Oncogene 35:4080-90
Zhou, Haiping; Wang, Xing; Mo, Lan et al. (2016) Role of isoenzyme M2 of pyruvate kinase in urothelial tumorigenesis. Oncotarget 7:23947-60
Madka, Venkateshwar; Mohammed, Altaf; Li, Qian et al. (2016) Targeting mTOR and p53 Signaling Inhibits Muscle Invasive Bladder Cancer In Vivo. Cancer Prev Res (Phila) 9:53-62
Liu, Zhongbo; Yokoyama, Noriko N; Blair, Christopher A et al. (2016) High Sensitivity of an Ha-RAS Transgenic Model of Superficial Bladder Cancer to Metformin Is Associated with ∼240-Fold Higher Drug Concentration in Urine than Serum. Mol Cancer Ther 15:430-8
Jiang, Guosong; Wu, Amy D; Huang, Chao et al. (2016) Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis. Cancer Prev Res (Phila) 9:567-80
Wankel, Bret; Ouyang, Jiangyong; Guo, Xuemei et al. (2016) Sequential and compartmentalized action of Rabs, SNAREs, and MAL in the apical delivery of fusiform vesicles in urothelial umbrella cells. Mol Biol Cell 27:1621-34
Liang, Yuguang; Zhu, Junlan; Huang, Haishan et al. (2016) SESN2/sestrin 2 induction-mediated autophagy and inhibitory effect of isorhapontigenin (ISO) on human bladder cancers. Autophagy 12:1229-39

Showing the most recent 10 out of 42 publications